Synucure Therapeutics inc. is a Canadian biotechnology company conducting research in brain degenerative disorders. Synucure was founded in 2021 with the key objective to pursue the promising and robust pre-clinical work of Dr. Francesca Cicchetti on a repurposed drug called Cysteamine which demonstrated, in various animal and cell models, that the drug could prevent and/or reverse a number of features related to Parkinson’s Disease (PD). Her research on the potential benefits of Cysteamine in neurodegenerative disorders was initiated 20 years ago.
In addition to the promising role of Cysteamine as a Disease Modifying Therapy (DMT) in Parkinson, Dr. Cicchetti and her colleagues conducted research on patented blood biomarkers, of which the main objective is to provide clinicians with a more precise diagnostic and stratification tool for the disease using a simple blood test.
If you need more information, please contact us at info@synucure.com
Company Details
- Employees
- 4
- Founded
- -
- Address
- Montreal , Ca
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://synucure.com
- Keywords
- en gouvernance.
- HQ
- Montreal
Synucure Therapeutics Questions
Synucure Therapeutics's website is https://synucure.com
Synucure Therapeutics's LinkedIn profile is https://ca.linkedin.com/company/synucure
Synucure Therapeutics has
4 employees.
View email and phone details for 4
employees at Synucure Therapeutics.
Synucure Therapeutics's industry is
Biotechnology Research
Synucure Therapeutics's top competitors are
Semathera Inc,
Kaster Technologies Inc.,
Histurn Fertility,
Acessa.com,
Nanobrand,
Psygen,
Polaris Oligonucleotides,
Laurent Pharmaceuticals,
Ai Works - For The People Co.,
Cerebro Therapeutics.
Synucure Therapeutics's categories are Biotechnology Research
Synucure Therapeutics's founding year is 2021
